Market Place
Sourcing Support
vTv Therapeutics To Join 7th Evercore HealthCONx Conference
02 Dec 2024 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2024 Q3 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
VTv Therapeutics Announces Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
FDA places vTv`s lead diabetes drug on hold over chromatographic signal
30 Jul 2024 //
FIERCE BIOTECH
vTv Therapeutics` Cadisegliatin For Type 1 Diabetes On Clinical Hold
26 Jul 2024 //
GLOBENEWSWIRE
vTv Therapeutics Begins CATT1 Trial For Cadisegliatin In Type 1 Diabetes
24 Jun 2024 //
GLOBENEWSWIRE
vTv Announces Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
vTv Announces FDA Submission for First Phase 3 Study of Cadisegliatin
04 Mar 2024 //
GLOBENEWSWIRE
vTv Therapeutics to Participate at TD Cowen 44th Annual Healthcare Conference
01 Mar 2024 //
GLOBENEWSWIRE
vTv Therapeutics Announces $51 Million Private Placement
28 Feb 2024 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2023 Third Quarter Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
08 Nov 2023 //
GLOBENEWSWIRE
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
02 Nov 2023 //
GLOBENEWSWIRE
vTv Therapeutics Announces Sale of Shares in Reneo for Proceeds of $4.4 Million
01 Nov 2023 //
PRESS RELEASE
vTv Therapeutics Announces 2023 Second Quarter Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Right
16 Jun 2023 //
GLOBENEWSWIRE
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon
24 May 2023 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2023 First Quarter Financial Results
11 May 2023 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Elizabeth Keiley Selected as Executive VP & General Counsel of vTv Therapeutics
01 Feb 2023 //
GLOBENEWSWIRE
vTv Therapeutics Appoints Industry Veteran Steven Tuch as CFO
13 Dec 2022 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2022 3Q Financial Results and Provides Update
10 Nov 2022 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2022 Second Quarter Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Former eGenesis CEO joins vTv as it tries to make a comeback; & MORE
29 Jul 2022 //
ENDPTS
vTv Therapeutics Announces Paul Sekhri as new President and CEO
27 Jul 2022 //
GLOBENEWSWIRE
vTv Therapeutics Announces Investment by CinRx Pharma
25 Jul 2022 //
GLOBENEWSWIRE
vTv Tx Announces Publication in Obesity and Metabolism of Effects of TTP399
04 Jun 2022 //
GLOBENEWSWIRE
vTv Therapeutics Enters Collaboration and License Agreement with G42 Healthcare
01 Jun 2022 //
GLOBENEWSWIRE
vTv Therapeutics Announces 2022 First Quarter Financial Results
12 May 2022 //
GLOBENEWSWIRE
vTv Tx Announces 2021 fourth Quarter and Full Year Financial Results
29 Mar 2022 //
PRNEWSWIRE
vTv Therapeutics Shares Updated Corporate Presentation
13 Jan 2022 //
GLOBENEWSWIRE
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program
07 Dec 2021 //
GLOBENEWSWIRE
vTv Drug Candidate Lowers Blood Sugar Without Increasing DKA Risk
12 Oct 2021 //
BIOSPACE
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating
12 Oct 2021 //
GLOBENEWSWIRE
vTv rises 26% after-hours on ascending dose study data, plans for phase 2 trial
23 Sep 2021 //
SEEKINGALPHA
vTv Announces Results of Multiple Ascending Dose Study and DevP Plan for HPP737
23 Sep 2021 //
GLOBENEWSWIRE
vTv Tx to Participate at 6th World Psoriasis & Psoriatic Arthritis Conference
29 Jun 2021 //
GLOBENEWSWIRE
vTv Therapeutics & Cantex Announce Strategic Licensing Agreement
22 Jun 2021 //
GLOBENEWSWIRE
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399
13 Apr 2021 //
GLOBENEWSWIRE
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of TTP399
23 Mar 2021 //
GLOBENEWSWIRE
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential
19 Mar 2021 //
GLOBENEWSWIRE
vTv Therapeutics Announces Initiation of Study Evaluating TTP399
18 Mar 2021 //
GLOBENEWSWIRE
vTv Announces in Diabetes Care of Results from SimpliciT-1 Study of TTP399
23 Feb 2021 //
GLOBENEWSWIRE
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737
17 Feb 2021 //
GLOBENEWSWIRE
vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study
15 Dec 2020 //
GLOBENEWSWIRE
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects i
04 Nov 2020 //
GLOBENEWSWIRE
vTv to Present Study Update and Preliminary Data on Baseline Characteristics
29 Oct 2020 //
GLOBENEWSWIRE
vTv Presents Positive Clinical Study Results in Patients with Type 1 Diabetes
23 Sep 2020 //
GLOBENEWSWIRE
vTv Therapeutics Presents Positive Clinical Study Results of TTP399
22 Sep 2020 //
BIOSPACE
vTv Therapeutics presents Positive Study Results from Phase 2 Simplici-T1 Study
16 Sep 2020 //
GLOBENEWSWIRE
vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study
27 Jul 2020 //
GLOBENEWSWIRE
vTv Therapeutics to Present Full Clinical Results Ph2 Simplici-T1 of TTP399
27 May 2020 //
GLOBENEWSWIRE
